All News
Increasing Incidence of Morphea
A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.
Read Article
ACR Speaks Against Repeated Cuts to Medicare Reimbursements
The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million Americans living with rheumatic disease.
Read Article
ACR Recommends QOL Self-Management Strategies
American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not a
Read Article
Consensus Guidelines on Pediatric Methotrexate Use
Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.
Read Article
Moving Forward on RA Prevention Trials
Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.
Read Article
Running with Data (8.30.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.
Read Article
ACR Backs FDA Rule Change on Interchangeable Biosimilars
The American College of Rheumatology submitted comments to the U.S. Food & Drug Administration supporting their recent proposal to update the approval process for biosimilars’ interchangeability status by repealing the requirement for switching studies while also encouraging the FDA to continue monitoring the downstream effects of this policy to ensure transparency for patients and prescribing providers.
Read Article
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.
Read Article
Less Mortality with GLP-1 Agonists in Rheumatic Patients
A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.
Read Article
The Burden of Rheumatoid Arthritis (2018–2020)
A recent study that quantified the economic and humanistic burden of rheumatoid arthritis (RA) in the USA showed significantly higher health care expenditures, particularly medication costs, and suboptimal quality of life in RA.
Read Article
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
Prescription Painkiller Misuse in Chronic Pain Patients
A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.
Read Article
Economic, Personal Burden of RA: Maybe Not So Bad?
Data from a major federal survey indicate that people with rheumatoid arthritis (RA) don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.
Read Article
Barriers to Treat-to-Target in Rheumatoid Arthritis
A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.
Read Article
Gout Forecast: 70% Increase by 2050
The Global Burden of Diseases, Injuries, and Risk Factors Study of 2021 has forecasted prevalence of gout to increase by 70% by 2050. In the USA, the prevalence of gout is estimated to be 10.3 million. As of 2020, 55.8 million people globally had gout, with a prevalence of 659.3 per 100 000 (this represents a 22.5% increase since 1990).
Read Article
Links:
